What one share of Bluejay Diagnostics holds
Bluejay Diagnostics, Inc. (“Bluejay”) is a medical diagnostics company focused on improving patient outcomes in critical care settings, with a focus on sepsis. We are working on developing rapid, near-patient tests using whole blood on our Symphony technology platform (“Symphony”), which consists of an analyzer and single-use protein detection cartridges.
Bluejay Diagnostics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$6.68 |
|---|---|
| Cash and investments | $4.84 |
| Book value | $4.75 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$456.75 | $6.69 | −$177.27 | — | — |
| 2025 | — | −$15.25 | $0.39 | −$13.87 | — | $9.88 |
Common questions about Bluejay Diagnostics
How much does one share of Bluejay Diagnostics earn?
Over the last 12 months, Bluejay Diagnostics lost $6.68 for each share.
Does Bluejay Diagnostics pay a dividend?
Bluejay Diagnostics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Bluejay Diagnostics’s book value per share?
Bluejay Diagnostics’s book value is $4.75 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Bluejay Diagnostics have?
Each share of Bluejay Diagnostics has $4.84 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.